Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jul 2015
Multicenter StudyA phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
Vismodegib is approved for treatment of advanced basal cell carcinoma. ⋯ Primary efficacy end points were not met (predefined complete histologic clearance rate: >50% in cohorts 1 and 3; >30% in cohort 2). Safety was comparable when dosed continuously versus intermittently. Posttreatment reversibility of vismodegib-related AEs was demonstrated.
-
J. Am. Acad. Dermatol. · Jun 2015
Multicenter StudyPivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Primary analysis from the pivotal ERIVANCE BCC study resulted in approval of vismodegib, a Hedgehog pathway inhibitor indicated for treatment of adults with metastatic or locally advanced basal cell carcinoma (BCC) that has recurred after surgery or for patients who are not candidates for surgery or radiation. ⋯ The 12-month update of the study confirms the efficacy and safety of vismodegib in management of advanced BCC.
-
J. Am. Acad. Dermatol. · Mar 2015
Multicenter StudyA prospective study of risk for Sturge-Weber syndrome in children with upper facial port-wine stain.
Upper facial port-wine stain (PWS) is a feature of Sturge-Weber syndrome (SWS). Recent studies suggest that the distribution of the PWS corresponds to genetic mosaicism rather than to trigeminal nerve impairment. ⋯ Specific PWS distribution patterns are associated with an increased risk of SWS. These PWS patterns conform to areas of somatic mosaicism. Terminology stipulating ophthalmic division of trigeminal nerve territory involvement in SWS should be abandoned.
-
J. Am. Acad. Dermatol. · Dec 2014
Multicenter StudyA 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Patients with moderate to severe plaque psoriasis demonstrated positive responses to ixekizumab, an anti-interleukin-17A monoclonal antibody, in a phase-II, randomized, placebo-controlled trial. ⋯ A high proportion of patients responded to ixekizumab therapy and maintained clinical responses over 1 year of treatment with no unexpected safety signals.
-
J. Am. Acad. Dermatol. · Oct 2014
Randomized Controlled Trial Multicenter Study Comparative StudyComparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics.
General practitioners/dermatologists may be aware of musculoskeletal symptoms in patients with psoriasis but may have difficulty accurately detecting psoriatic arthritis (PsA). ⋯ PASQ, PEST, and ToPAS are useful screening tools that can help dermatologists identify patients without PsA and patients with possible PsA who may benefit from rheumatologist assessment.